For research use only. Not for therapeutic Use.
MPT0B014 is a tubulin polymerization inhibitor. MPT0B014 induces cancer cell apoptosis. MPT0B014 can be used for the research of cancer[1].
MPT0B014 (0-1 μM; 48 h) inhibits A549, H1299 and H226 cells growth in a dose-dependent manner[1].
MPT0B014 (0.05-0.3 μM; 24 and 48 h) arrests cell cycle at G2/M and sub-G1 phases and induces apoptosis in A549 cells[1].
The combination of MPT0B014 (100 mg/kg; i.v./i.p.; daily for 25 days) and 25 mg/kg Erlotinib (HY-50896) significantly improves A549 tumor inhibition in mice[1].
| Catalog Number | R067015 |
| CAS Number | 1215208-59-5 |
| Synonyms | quinolin-6-yl-(3,4,5-trimethoxyphenyl)methanone |
| Molecular Formula | C19H17NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17NO4/c1-22-16-10-14(11-17(23-2)19(16)24-3)18(21)13-6-7-15-12(9-13)5-4-8-20-15/h4-11H,1-3H3 |
| InChIKey | GSGXITQZCMSYKF-UHFFFAOYSA-N |
| SMILES | COC1=CC(=CC(=C1OC)OC)C(=O)C2=CC3=C(C=C2)N=CC=C3 |
| Reference | [1]. Tsai AC, et al. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. Br J Pharmacol. 2014 Jan;171(1):122-33. |
